Weight Loss
GLP-1 receptor agonists and next-generation weight loss peptides. Tirzepatide, Retatrutide, and the science behind sustainable fat loss.
Retatrutide
Retatrutide is a triple hormone receptor agonist (GIP, GLP-1, and glucagon) currently in Phase III trials. Early trial data shows up to 24% body weight reduction — potentially the most powerful weight loss peptide in development.
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist originally developed for type 2 diabetes that has demonstrated exceptional weight loss results — up to 22% body weight reduction in clinical trials. It acts on two complementary hormonal pathways to suppress appetite and improve metabolic function.
Research use only. All content on The Peptide Primer is provided for educational and informational purposes only. Nothing on this site constitutes medical advice. Peptides discussed are not FDA-approved for human use unless otherwise noted. Always consult a qualified healthcare professional before making health-related decisions.